Cancer Biomarker Testing Market Some of the Players Included in the Report are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.)

Cancer Biomarker Testing Market
The cancer biomarker test market is driven by rising prevalence of cancer worldwide. World Health Organization (WHO) stated that cancer is one of the leading causes of mortality and morbidity worldwide, with approximately 14 Mn new cases in 2013. The number of new cases is expected to rise about 70% over the coming 2 decades. In addition, increase in awareness in public and healthcare professionals regarding early diagnostic procedures, rise in government and NGO’s funding for oncology are expected to bolster the Cancer Biomarker Testing Market. Furthermore, the development of companion diagnostics and recent breakthrough in detection techniques such as proteomics, metabolomics, genomics and transcriptomics are further expected to boost the cancer biomarker test market. However, high cost for biomarker tests, low detection rates and regulatory policies are expected to hamper the cancer biomarker test market.

Some of the players in cancer biomarker test market are Thermo Fisher Scientific (Affymetrix Inc.) (U.S.), Abbott Laboratories (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), AbbVie Inc. (U.S.), Arquer Diagnostics Ltd. (U.K.), Illumina, Inc. (U.S.), Qiagen (Germany), Agilent Technologies (U.S.), Merck & Co. Inc. (U.S.), Becton Dickinson and Company (U.S.), and Hologic Inc. (U.S.) to name a few.

Get Free Sample Report@ https://www.qurateresearch.com/report/sample/HnM/QBI-PBI-HnM-3162

Cancer Biomarker Testing Market: Biomarker is any of body molecules that can be measured to assess the health. Molecules can be obtained from, body fluids, tissue or blood. Biomarker testing is also known as genetic testing or molecular testing. Biomarker test is a group of tests that look for these molecular signs of health so that doctors can plan best care. Cancer is referred as abnormal growth of the cells. Cancer biomarker is a process or substance that indicates the presence of cancer in the body. Genetic, epigenetic, glycemic, proteomic, and imaging biomarkers are used for cancer diagnosis, prognosis, and epidemiology. These cancer biomarkers used as risk indicators for various types of cancer such as lung cancer, breast cancer and prostate cancer among the others. Key cancer biomarkers include SCC, CEA, NSE Cyfra 21, PSA (prostate cancer), TPA (Lung cancer), CA15-3, EGF R, Cytokeratin 4 (breast cancer) and BRCA ½.

In 2015, Abbot Laboratories acquired exclusive rights for FGFR3 gene mutations to detect bladder cancer. FGFR3 developed at Institute Curie, it is a gene mutation and useful for early detection, disease monitoring, and prognosis of bladder cancer through tissue and urine-based testing

Enquiry about Report@ https://www.qurateresearch.com/report/enquiry/HnM/QBI-PBI-HnM-3162/

Cancer biomarker testing market segmented based on type of cancer, application, bio molecule and end user
Based on type of cancer, cancer biomarker test market is segmented into
Cervical cancer
Lung Cancer
Collateral Cancer
Liver Cancer
Prostate Cancer
Breast Cancer
Others

Based on application, cancer biomarker test market is segmented into
Drug Discovery and Development
Personalised Medicine
Diagnosis
Others

Based on end-user, cancer biomarker test market is segmented into
Hospitals
Cancer diagnostic Centres
Research Institutes
Others

Get Discount@ https://www.qurateresearch.com/report/discount/HnM/QBI-PBI-HnM-3162/

The global cancer biomarker test market is expected to grow with significant CAGR during forecast period. Market players are carrying out collaborations, partnerships, and acquisitions as key development strategies to enhance the market share. For instance, in March 2018, Foundation Medicine and Bristol-Myers Squibb entered collaboration to understand tumour profile and its microenvironment to predict patient’s response to cancer immunotherapy. Using Foundation Medicine’s foundation genomic profiling assay, the firm will look at tumour mutational burden and microsatellite instability in patients enrolled in clinical trials for Bristol-Myers Squibb (BMS) cancer drugs. For instance, in October 2017, Arquer Diagnostics Ltd. (Arquer), and University of Sunderland are collaborated to investigate noninvasive specimen preparation techniques that will facilitate the use of Arquer’s MCM5-ELISA test in a wide range of cancers. In April 2017, Stemcentrix acquired by AbbiVe along with its lead late stage biomarker rovalpituzumab tesirine (Rova-T), that helps to identify tumour cells.

Geographically cancer biomarker testing market segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America is expected to be a major market for cancer biomarker test market owing to increase in research and development activities to diagnose and treating cancer and rise in prevalence of cancer. According to American Cancer Society (ACS), in 2018, it estimates 1,688,780 new cancer cases are diagnosed and 600,920 cancer deaths in the U.S. alone. Asia-Pacific region is expected to be fastest growing market due to increase in demand for the non-invasive techniques in diagnosis and prevention of cancer, high prevalence of cancer conditions in the region.

Buy This Report@ https://www.qurateresearch.com/report/buy/HnM/QBI-PBI-HnM-3162/

About Us:
Qurate Business Intelligence delivers unique market research solutions to its customers and help them to get equipped with refined information and market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Runwal Platinum,
Ramnagar Colony, Bavdhan,
Pune, Maharashtra, India-411021
IN +919881074592
info@qurateresearch.com
https://www.qurateresearch.com/

This release was published on openPR.